What has the U.S. Food & Drug Administration (FDA) said about the issue of insulin glargine and cancer?
Based on the currently available data, the FDA recommends that patients should not stop taking their insulin therapy without consulting a physician, since uncontrolled blood glucose levels can have both immediate and long-term serious adverse effects. FDA is currently reviewing many sources of safety data for Lantus, including these newly published observational studies, data from all completed controlled clinical trials, and information about ongoing controlled clinical trials, to better understand the risk, if any, for cancer associated with use of Lantus. Discussions are also ongoing between FDA and the manufacturer of Lantus as to whether any additional studies evaluating the safety and efficacy of this drug will need to be performed. FDA will communicate the results on its ongoing review to the public, as appropriate, as our review continues.
Related Questions
- When did the U.S. Food & Drug Administration (FDA) require that pancreatic enzyme products (PEPs) receive formal FDA-approval?
- Why does the U.S. Food & Drug Administration (FDA) make it difficult to get B17 and Laetrile (and the real facts about them)?
- Are flower essences regulated by the FDA (Food & Drug Administration)?
